Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

NCT03477500 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Cyclophosphamide and ATG
DRUG: Alemtuzumab
DRUG: Cladribine Pill
DRUG: Ocrelizumab

Sponsor

Haukeland University Hospital